Stay Up to Date
Breaking News,
Updates, & More
Click Here to
Subscribe
Home
Issues
2022
May 2022 - Vol 15 No 3
March 2022 - Vol 15 No 2
January 2022 - Vol 15 No 1 – Online Only
2021
November 2021 - Vol 14 No 7
October 2021 - Vol 14 No 6 | Biosimilars
September 2021 - Vol 14 No 5
July 2021 - Vol 14 No 4
May 2021 - Vol 14 No 3
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Part 1
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Ovarian Cancer Overview
Interview with the Innovators
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Wayne Kuznar
Authored Items
Two Ways to Target Tumors with KRAS Mutations
Wayne Kuznar
Web Exclusives
in
AACR Highlights
Nivolumab Bridges Patients with Relapsed/Refractory Hodgkin Lymphoma to AHCT
Wayne Kuznar
TOP - March 2020, Vol 13, No 2
in
ASH 2019 Highlights
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy Prevents Cytokine Release Syndrome
Wayne Kuznar
TOP - March 2020, Vol 13, No 2
in
ASH 2019 Highlights
Investigational BET Inhibitor, CPI-0610, Promotes Responses in Myelofibrosis
Wayne Kuznar
TOP - March 2020, Vol 13, No 2
in
ASH 2019 Highlights
Neoantigens Are Effective Targets for Developing Cancer Vaccines
Wayne Kuznar
TOP - November 2019, Vol 12, No 4
in
Emerging Therapies
Repotrectinib, an Investigational TKI, Induces Response in ROS1-Fusion–Positive NSCLC
Wayne Kuznar
TOP - August 2019, Vol 12, No 3
in
Lung Cancer
Single-Agent ONC201 Induces Responses in Patients with Hard-to-Treat Recurrent High-Grade Glioma
Wayne Kuznar
TOP - August 2019, Vol 12, No 3
in
Emerging Therapies
NCI-COG Pediatric MATCH Trial Shows High Rate of Targetable Molecular Alterations
Wayne Kuznar
TOP - August 2019, Vol 12, No 3
in
Pediatric Cancer
Tumor Metabolism-Altering Regimen Achieves Clinical Benefit in Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Pancreatic Cancer
Sacituzumab, a Novel Antibody-Drug Conjugate, Shows Activity in Heavily Pretreated Urothelial Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Urothelial Cancer
Adding PARP Inhibitor to Immune Checkpoint Blockade Improves Responses in Ovarian Cancer with BRCA Mutations
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Ovarian Cancer
Personalized Neoadjuvant Immunotherapy Combinations Improve Outcomes in Stage III Melanoma
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Melanoma
Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Lung Cancer
Immunotherapy Moving into Earlier Lines of Lung Cancer Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Lung Cancer
CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Immunotherapy
Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Immunotherapy
CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Immunotherapy
Immunotherapy Combination Extends Survival in Advanced Refractory Colorectal Cancer
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Colorectal Cancer
Updated NCCN Breast Cancer Guideline Expands Treatment Recommendations for HR-Positive, HER2-Negative Disease
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
Breast Cancer
,
NCCN
Immunotherapy Strategies in the Updated NCCN Guideline for NSCLC Hinge on PD-L1 Testing
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
NCCN
Updated NCCN Treatment Guideline for CML Establishes Criteria for Stopping TKI Therapy
Wayne Kuznar
TOP - May 2019, Vol 12, No 2
in
NCCN
Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma
Wayne Kuznar
TOP - February 2019, Vol 12, No 1
in
Immunotherapy
,
Renal-Cell Carcinoma
High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected
Wayne Kuznar
TOP - November 2018, Vol 11, No 3
in
Lynch Syndrome
Pomalidomide Added to the Regimen in First Relapse Extends PFS in Multiple Myeloma
Wayne Kuznar
Web Exclusives
in
Multiple Myeloma
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
Web Exclusives
in
FDA Updates
NCCN Issues First Guideline for Immunotherapy-Related Adverse Events
Wayne Kuznar
Web Exclusives
in
Side-Effects Management
NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease
Wayne Kuznar
Web Exclusives
in
NCCN News
,
NCCN
Regorafenib Dose-Escalation Strategy Potentially a New Standard in Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2
in
Colorectal Cancer
Immunotherapy Combination Shows Durable Responses in Mismatch Repair–Deficient Metastatic Colorectal Cancer
Wayne Kuznar
TOP - August 2018, Vol 11, No 2
in
Immunotherapy
Cediranib-Based Combination Therapy Extends Progression-Free Survival in Relapsed Ovarian Cancer
Wayne Kuznar
TOP - November 2017, Vol 10, No 4
in
Gynecologic Cancers
,
Online First
Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancers
Wayne Kuznar
TOP - November 2017, Vol 10, No 4
in
Breast Cancer
Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases Myeloma
Wayne Kuznar
TOP - November 2017, Vol 10, No 4
in
Lung Cancer
Updated NCCN Guidelines for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
Wayne Kuznar
TOP - August 2017, Vol 10, No 3
in
Conference Correspondent
,
NCCN News
,
NCCN
Duloxetine Improves Chemotherapy-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer
Wayne Kuznar
TOP - May 2017, Vol 10, No 2
in
Pancreatic Cancer
Venetoclax plus Bortezomib and Dexamethasone Produces High Responses in Relapsed or Refractory Multiple Myeloma
Wayne Kuznar
Web Exclusives
in
Conference Correspondent
,
In the News
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Wayne Kuznar
Web Exclusives
in
Conference Correspondent
,
In the News
Alectinib for First-Line Treatment in NSCLC with ALK Mutation
Wayne Kuznar
TOP - November 2016, Vol 9, No 4
in
Conference Correspondent
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
Wayne Kuznar
TOP - August 2016, Vol 9, No 3
NCCN Survivorship Guidelines Update Management of Sexual Dysfunction in Cancer Survivors
Wayne Kuznar
TOP - August 2016, Vol 9, No 3
Promising Antitumor Activity of ODM-201 in Metastatic Prostate Cancer
Wayne Kuznar
TOP - August 2016, Vol 9, No 3
in
Genitourinary Cancers
Text Messaging Application Helpful with Adherence to Endocrine Therapy
Wayne Kuznar
TOP - May 2016, Vol 9, No 2
Scalp Cooling System Lessens Chemotherapy-Induced Alopecia
Wayne Kuznar
TOP - February 2016, Vol 9, No 1
in
Breast Cancer
Oncology Specialty Pharmacy Promotes the Coordination of Care
Wayne Kuznar
TOP November 2015 Vol 8 No 4
in
Practical Issues for Pharmacists
Immune Checkpoint Blockade Shows Durable Responses in Lung and Kidney Cancers, Metastatic Melanoma
Wayne Kuznar
TOP - August 2015, Vol 8, No 3
NCCN Issues New Smoking-Cessation Guidelines for Patients with Cancer
Wayne Kuznar
TOP - August 2015, Vol 8, No 3
Treatment for CLL Will Incorporate More Targeted Therapies in the Near Future
Wayne Kuznar
TOP - August 2015, Vol 8, No 3
in
Hematologic Cancers
Vosaroxin, a Quinolone Derivative, Extends Survival in Older Patients with Acute Myeloid Leukemia
Wayne Kuznar
TOP - May 2015, Vol 8, No 2
in
Hematologic Cancers
Monitoring Response to TKI Therapy by PCR Improves Outcomes in Chronic Myeloid Leukemia
Wayne Kuznar
TOP - May 2015, Vol 8, No 2
in
Hematologic Cancers
Immunotherapy the Newest Breakthrough in Hodgkin Lymphoma
Wayne Kuznar
TOP - February 2015, Vol 8, No 1
in
Immunotherapy
Cancer Drug Pricing in the United States: What Is Driving the High Costs?
Wayne Kuznar
TOP - February 2015, Vol 8, No 1
in
Conference Correspondent
Health Literacy
Wayne Kuznar
TOP - August 2014, Vol 7, No 3
in
Noteworthy Numbers
Worksite Pharmacy Can Enhance Overall Drug Management of Patients With Cancer
Wayne Kuznar
TOP - August 2014, Vol 7, No 3
in
Conference Correspondent
Investigational Angiogenesis Inhibitor Ramucirumab Improves Survival as Second-Line Treatment
Wayne Kuznar
TOP - May 2014, Vol 7, No 2
in
Gastrointestinal Cancers
Immunotherapy Holds Promise to Extend Survival in GI Cancers
Wayne Kuznar
TOP - May 2014, Vol 7, No 2
Promising Vaccine Combination Identified for Patients With Metastatic Pancreatic Cancer
Wayne Kuznar
TOP - May 2014, Vol 7, No 2
in
Rare Cancers
Molecular Therapy Beyond Sorafenib in HCC: New Pathways, Targets Being Explored
Wayne Kuznar
TOP - May 2014, Vol 7, No 2
in
Genitourinary Cancers
Hormone Therapy Poses Health Risks in Patients With Prostate Cancer
Wayne Kuznar
TOP - May 2014, Vol 7, No 2
in
Hematologic Cancers
Molecular Monitoring Can Provide Treatment Guidance in CML
Wayne Kuznar
TOP - May 2014, Vol 7, No 2
in
Hematologic Cancers
Skin Toxicity With Targeted Agents: Treatment With Antibiotics, Topical Steroids Often Sufficient
Wayne Kuznar
TOP - May 2014, Vol 7, No 2
in
Supportive Care
Monitor Adverse Events Early With Regorafenib, Especially After Initiation
Wayne Kuznar
TOP - May 2013, Vol 6, No 2
in
Supportive Care
Quality of Life Drives Patient Preference for Metastatic Renal Cell Carcinoma Drug
Wayne Kuznar
TOP - August 2012, Vol 5, No 5
Most End-of-Life Costs for Patients with Cancer Are Not Drug Related
Wayne Kuznar
TOP - September 2011 Vol 4, No 6
in
Conference Correspondent
Get Ready for the New Era of “Genomic Chaos” in Cancer Care
Wayne Kuznar
TOP - September 2011 Vol 4, No 6
in
Conference Correspondent
Decitabine Improves Overall Survival in Older AML Patients
Wayne Kuznar
TOP - August 2011 Vol 4, No 5
in
Conference Correspondent
,
Conference Correspondent
,
Hematologic Cancers
Treating Breakthrough Cancer Pain Requires Recognition, Matching Drug to Goal
Wayne Kuznar
Web Exclusives
in
Supportive Care
Managing Hypersensitivity Reactions
Wayne Kuznar
Web Exclusives
in
Supportive Care
Managing Hypersensitivity Reactions
Wayne Kuznar
Web Exclusives
in
Supportive Care
Pharmacist Review of Palonosetron Use Has Potential to Capture Inappropriate Use and Save Money
Wayne Kuznar
Web Exclusives
in
Drug Therapies
For Overweight Patients, Dosing Chemotherapy Based on Total Body Weight Does Not Lead to More Toxicities
Wayne Kuznar
Web Exclusives
in
Gastrointestinal Cancers
Hospital Implements New Oral Chemotherapy Handling Process in Effort to Increase Safety
Wayne Kuznar
Web Exclusives
Timing of Empiric Antibiotic Administration Affects Outcomes in Febrile Neutropenia
Wayne Kuznar
TOP - February 2011, Vol 4, No 1
Hospital Implements New Oral Chemotherapy Handling Process in Effort to Increase Safety
Wayne Kuznar
Web Exclusives
Pharmacist Review of Palonosetron Use has Potential to Capture Inappropriate Use and Save Money
Wayne Kuznar
Web Exclusives
For Overweight Patients, Dosing Chemotherapy Based on Total Body Weight Does Not Lead to More Toxicities
Wayne Kuznar
Web Exclusives
Denosumab Prevents More Skeletal Events than Zoledronic Acid in Men with Prostate Cancer and Bone Metastases
Wayne Kuznar
Web Exclusives
Naproxen Reduces Bone Pain after Pegfilgrastim Injection
Wayne Kuznar
Web Exclusives
Risk Factors for Chemotherapy Toxicity in Elderly are Identified
Wayne Kuznar
Web Exclusives
Fentanyl Nasal Spray Beats Oral Opioid for Control of Rreakthrough Cancer Pain
Wayne Kuznar
Web Exclusives
Naproxen Reduces Bone Pain After Pegfilgrastim Injection
Wayne Kuznar
Web Exclusives
Bevacizumab Lengthens Progression-free Survival in Advanced Ovarian Cancer
Wayne Kuznar
Web Exclusives
Last modified: June 10, 2010
Home
Issues
2022
May 2022 - Vol 15 No 3
March 2022 - Vol 15 No 2
January 2022 - Vol 15 No 1 – Online Only
2021
November 2021 - Vol 14 No 7
October 2021 - Vol 14 No 6 | Biosimilars
September 2021 - Vol 14 No 5
July 2021 - Vol 14 No 4
May 2021 - Vol 14 No 3
March 2021 - Vol 14 No 2
January 2021 - Vol 14 No 1
2020
November 2020, Vol 13, No 6
September 2020 - Vol 13 no 5
July 2020 - Vol 13 no 4
May 2020 - Vol 13 no 3
March 2020 - Vol 13 no 2
January 2020 - Vol 13 No 1
2019
November 2019 - Vol 12 No 4
August 2019 - Vol 12 No 3
May 2019 - Vol 12 No 2
February 2019 - Vol 12 No 1
Issue Archive
Special Issues
Supplements
ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
Part 1
Guide to New FDA Approvals
2019 Fourth Annual Guide
2018 Third Annual Guide
2017 Second Annual Guide
2016 First Annual Guide
Categories
Conference Correspondent
ASCO 2021 Wrap-Up - Breast Cancer
Web Exclusives
Ovarian Cancer Overview
Interview with the Innovators
All Web Exclusives
Drug Updates
FDA Approvals, News & Updates
In the News
Press Releases
Online First
Media Library
Videos
Audiocasts
Quick Quiz
CE
About
About TOP
Advertise
Editorial Board
Contact Us
Resources
Submit
Author Guidelines
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
TOP
Print Edition
We will request your mailing address on the next page.
TOP
E-Newsletters and Communications
JHOP
Print Edition
We will request your mailing address on the next page.
JHOP
E-Newsletters and Communications
I have reviewed and consent to the terms of
TOP
's
Privacy Policy
, and
TOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
